Alamar Biosciences, Inc. 10-Q filing
Filed 2026-05-08 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-213424
- Form type
- 10-Q
- CIK
- 0002104204
- Primary document
- https://www.sec.gov/Archives/edgar/data/2104204/000119312526213424/ck0002104204-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Alamar Biosciences, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $26.0M | - | - |
| Cost Of Revenue | $11.6M | - | - |
| Gross Profit | $14.5M | - | - |
| Operating Income | $-12.3M | - | - |
| Net Income | $-21.3M | - | - |
| Eps Basic | -1.74 | - | - |
| Eps Diluted | -1.74 | - | - |
| Cash And Equivalents | $64.6M | - | - |
| Total Assets | $186.5M | - | - |
| Total Liabilities | $129.5M | - | - |
| Shareholders Equity | $-178.1M | - | - |
| Operating Cash Flow | $-20.3M | - | - |
| Capital Expenditures | $600,000 | - | - |